413 related articles for article (PubMed ID: 23725370)
1. Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation.
García-Reyne A; Lumbreras C; Fernández I; Colina F; Abradelo M; Magan P; San-Juan R; Manrique A; López-Medrano F; Fuertes A; Lizasoain M; Moreno E; Aguado JM
Transpl Infect Dis; 2013 Aug; 15(4):405-15. PubMed ID: 23725370
[TBL] [Abstract][Full Text] [Related]
2. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
3. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection.
Yoshida EM; Lilly LB; Marotta PJ; Mason AL; Bilodeau M; Vaillancourt M
Ann Hepatol; 2013; 12(2):282-93. PubMed ID: 23396740
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.
Song AT; Sobesky R; Vinaixa C; Dumortier J; Radenne S; Durand F; Calmus Y; Rousseau G; Latournerie M; Feray C; Delvart V; Roche B; Haim-Boukobza S; Roque-Afonso AM; Castaing D; Abdala E; D'Albuquerque LA; Duclos-Vallée JC; Berenguer M; Samuel D
World J Gastroenterol; 2016 May; 22(18):4547-58. PubMed ID: 27182164
[TBL] [Abstract][Full Text] [Related]
5. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
Rosen HR; Shackleton CR; Higa L; Gralnek IM; Farmer DA; McDiarmid SV; Holt C; Lewin KJ; Busuttil RW; Martin P
Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
[TBL] [Abstract][Full Text] [Related]
6. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study.
Belli LS; Burroughs AK; Burra P; Alberti AB; Samonakis D; Cammà C; De Carlis L; Minola E; Quaglia A; Zavaglia C; Vangeli M; Patch D; Dhillon A; Cillo U; Guido M; Fagiuoli S; Giacomoni A; Slim OA; Airoldi A; Boninsegna S; Davidson BR; Rolles K; Pinzello G
Liver Transpl; 2007 May; 13(5):733-40. PubMed ID: 17370330
[TBL] [Abstract][Full Text] [Related]
7. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection.
Kuo A; Tan V; Lan B; Khalili M; Feng S; Roberts JP; Terrault NA
Liver Transpl; 2008 Oct; 14(10):1491-7. PubMed ID: 18825708
[TBL] [Abstract][Full Text] [Related]
8. Explanted liver inflammatory grade predicts fibrosis progression in hepatitis C recurrence.
Ghabril M; Dickson RC; Krishna M; Machicao V; Aranda-Michel J; Bonatti H; Nguyen JH
Liver Transpl; 2011 Jun; 17(6):685-94. PubMed ID: 21618689
[TBL] [Abstract][Full Text] [Related]
9. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis.
Berenguer M; Prieto M; Palau A; Rayón JM; Carrasco D; Juan FS; López-Labrador FX; Moreno R; Mir J; Berenguer J
Liver Transpl; 2003 Mar; 9(3):228-35. PubMed ID: 12619018
[TBL] [Abstract][Full Text] [Related]
10. Impact of Cytomegalovirus Infection on Severe Hepatitis C Recurrence in Patients Undergoing Liver Transplantation.
Caston JJ; Castells L; Varo E; Gomez MA; de la Mata M; Campos-Varela I; Lumbreras C; Gonzalez-Dieguez L; Fabregat J; Herrero I; Salcedo M; Sanchez-Antolín G; Torre-Cisneros J
Transplantation; 2016 Mar; 100(3):593-9. PubMed ID: 26371595
[TBL] [Abstract][Full Text] [Related]
11. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
12. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C.
Rayhill SC; Wu YM; Katz DA; Voigt MD; Labrecque DR; Kirby PA; Mitros FA; Kalil RS; Miller RA; Stolpen AH; Schmidt WN
Transplantation; 2007 Aug; 84(3):331-9. PubMed ID: 17700157
[TBL] [Abstract][Full Text] [Related]
13. [The recurrence of hepatitis C virus after liver transplantation].
Nemes B; Sárváry E; Gerlei Z; Fazakas J; Doros A; Németh A; Görög D; Fehérvári I; Máthé Z; Gálffy Z; Pár A; Schuller J; Telegdy L; Fehér J; Lotz G; Schaff Z; Nagy P; Járay J; Lengyel G
Orv Hetil; 2007 Oct; 148(42):1971-9. PubMed ID: 17932003
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor β1 polymorphisms and progression of graft fibrosis after liver transplantation for hepatitis C virus--induced liver disease.
Eurich D; Bahra M; Boas-Knoop S; Lock JF; Golembus J; Neuhaus R; Neuhaus P; Neumann UP
Liver Transpl; 2011 Mar; 17(3):279-88. PubMed ID: 21384510
[TBL] [Abstract][Full Text] [Related]
15. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection.
Delladetsima JK; Boletis JN; Makris F; Psichogiou M; Kostakis A; Hatzakis A
Liver Transpl Surg; 1999 Jul; 5(4):294-300. PubMed ID: 10388502
[TBL] [Abstract][Full Text] [Related]
16. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
Manousou P; Samonakis D; Cholongitas E; Patch D; O'Beirne J; Dhillon AP; Rolles K; McCormick A; Hayes P; Burroughs AK
Liver Transpl; 2009 Dec; 15(12):1783-91. PubMed ID: 19938143
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.
Vukotic R; Conti F; Fagiuoli S; Morelli MC; Pasulo L; Colpani M; Foschi FG; Berardi S; Pianta P; Mangano M; Donato MF; Malinverno F; Monico S; Tamè M; Mazzella G; Belli LS; Viganò R; Carrai P; Burra P; Russo FP; Lenci I; Toniutto P; Merli M; Loiacono L; Iemmolo R; Degli Antoni AM; Romano A; Picciotto A; Rendina M; Andreone P;
J Viral Hepat; 2017 Oct; 24(10):858-864. PubMed ID: 28370880
[TBL] [Abstract][Full Text] [Related]
18. Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course.
Gallegos-Orozco JF; Yosephy A; Noble B; Aqel BA; Byrne TJ; Carey EJ; Douglas DD; Mulligan D; Moss A; de Petris G; Williams JW; Rakela J; Vargas HE
Liver Transpl; 2009 Dec; 15(12):1872-81. PubMed ID: 19938138
[TBL] [Abstract][Full Text] [Related]
19. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
Prieto M; Berenguer M; Rayón JM; Córdoba J; Argüello L; Carrasco D; García-Herola A; Olaso V; De Juan M; Gobernado M; Mir J; Berenguer J
Hepatology; 1999 Jan; 29(1):250-6. PubMed ID: 9862874
[TBL] [Abstract][Full Text] [Related]
20. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
J Hepatol; 2006 Apr; 44(4):717-22. PubMed ID: 16487616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
